Dyne Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.dyne-tx.com

Market Cap $2.53B
PE -10
Debt $NaN
Cash $610.12M
EV $NaN
FCF -$220.31M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$257.60M
EBIT	-$271.08M
ROE	-33%
ROA	-33%
FCF	-$220.31M
Equity	$775.19M
Growth Stability	1
PE	-9.84
PB	3.27
P/FCF	-11.5
Price/Cash	0.24
Equity CAGR	60%
Earnings Growth YoY	0%

Earnings Growth QoQ	-1%
Equity CAGR 5Y	60%
Equity CAGR 3Y	-5%
Market Cap	$2.53B
Assets	$825.88M
Cash	$610.12M
Shares Outstanding	86.59M
Working Capital	762.57M
Current Ratio	26.63
Shares Growth 3y	7%
Equity Growth QoQ	62%
Equity Growth YoY	275%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

SEC Filings

Direct access to Dyne Therapeutics, Inc. (DYN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Dyne Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Dyne Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Dyne Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Dyne Therapeutics, Inc..

Years

Calculation mode

= -$2.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$220M	-$220M	-$220M	-$220M	-$220M	-$220M	-$220M	-$220M	-$220M	-$220M	-$220M	-$2.2B
DCF		-$200M	-$182M	-$166M	-$150M	-$137M	-$124M	-$113M	-$103M	-$93M	-$85M	-$849M
Value	-$2.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-
ROA	-	-17%	-35%	-56%	-147%	-33%
ROE	-	-17%	-41%	-67%	-258%	-33%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-
Earnings YoY growth	-	299%	151%	13%	40%	-
Equity YoY growth	-	2K%	8%	-31%	-64%	60%
FCF YoY growth	-	254%	158%	27%	21%	-